Sarepta Therapeutics, Inc. (SRPT)
- Previous Close
127.39 - Open
127.53 - Bid 128.55 x 200
- Ask 128.82 x 200
- Day's Range
125.62 - 131.46 - 52 Week Range
55.25 - 159.89 - Volume
956,749 - Avg. Volume
840,158 - Market Cap (intraday)
12.169B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-5.79 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
165.89
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
www.sarepta.comRecent News: SRPT
Performance Overview: SRPT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRPT
Valuation Measures
Market Cap
12.17B
Enterprise Value
11.89B
Trailing P/E
--
Forward P/E
45.45
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.57
Price/Book (mrq)
14.16
Enterprise Value/Revenue
9.56
Enterprise Value/EBITDA
-26.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.11%
Return on Assets (ttm)
-5.24%
Return on Equity (ttm)
-86.15%
Revenue (ttm)
1.24B
Net Income Avi to Common (ttm)
-535.98M
Diluted EPS (ttm)
-5.79
Balance Sheet and Cash Flow
Total Cash (mrq)
1.68B
Total Debt/Equity (mrq)
162.55%
Levered Free Cash Flow (ttm)
-347.96M
Research Analysis: SRPT
Company Insights: SRPT
SRPT does not have Company Insights